Novavax Inc. (NVAX) saw its stock surge 7.61% over a 24-hour period, driven by the company's announcement of selling its manufacturing facility in Bohumil, Czech Republic, to Novo Nordisk for $200 million.
The agreement involves the transfer of a 150,000-square foot state-of-the-art recombinant protein manufacturing facility, along with the existing workforce and related infrastructure. Novavax will receive a cash payment of $190 million in 2024 and an additional $10 million in 2025.
According to Novavax, the sale aligns with the company's strategy to evolve into a leaner and more agile organization focused on partnering its pipeline assets and proven technology platform. Moreover, the company expects annual operating cost reductions of approximately $80 million from the sale.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.